- Branża: Government; Health care
- Number of terms: 6957
- Number of blossaries: 0
- Company Profile:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for ...
A recombinant, soluble, hexameric fusion protein consisting of three human Fas ligand (FasL) extracellular domains fused to the dimer-forming collagen domain of human adiponectin with potential pro-apoptotic and antineoplastic activities. Assembled into a soluble hexameric structure mimicking the ligand clustering of endogenous active FasL, Fas receptor agonist APO010 activates the Fas receptor, resulting in caspase-dependent apoptosis in susceptible tumor cell populations. FasL is a transmembrane protein of the tumor necrosis factor (TNF) superfamily and a pro-apoptotic ligand for the death receptor Fas.
Industry:Pharmaceutical
A regimen consisting of doxorubicin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide, given in combination with radiation therapy and used for the treatment of high-risk, childhood Hodgkin's lymphoma. (NCI Thesaurus)
Industry:Pharmaceutical
A regimen containing doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate and etoposide used in combination with radiation therapy for the treatment of low-risk, childhood Hodgkin lymphoma. (NCI Thesaurus)
Industry:Pharmaceutical
A replication competent retroviral vector, derived from the Moloney murine leukemia virus (MoMLV), encoding a modified form of the yeast suicide gene cytosine deaminase (CD) (Toca 511) used as an antineoplastic adjuvant. Upon transcranial injection, retroviral virus vector encoding CD preferentially enters and transfects tumor cells, and expresses cytosine deaminase, an enzyme that catalyzes the intracellular conversion of the prodrug flucytosine (5-FC) into the antineoplastic agent 5-fluorouracil (5-FU). After administration of 5-FC, the tumor can be eradicated upon activation of 5-FU.
Industry:Pharmaceutical
A replication incompetent adenoviral vector encoding the full-length tumor suppressor gene Reduced Expression in Immortalized Cells (REIC or DKK3) (ad-REIC/DKK3), with potential antineoplastic activity. Upon intratumoral injection, tumor cells express REIC/DKK3 protein. This may result in the activation of c-Jun-NH2-kinase (JNK) and ultimately apoptosis via Bcl2 suppression and caspase-3 activation. Expression of REIC/DKK3 is normal in healthy cells but reduced or absent in many cancer cells; Forced overexpression of REIC/DKK3 in cancer cells may lead to an induction of tumor cell apoptosis and reduction of tumor cell growth while sparing normal, healthy cells naturally expressing endogenous REIC/DKK3.
Industry:Pharmaceutical
A replication-defective (ICP4-deleted) herpes simplex virus type 1 (HSV-1) viral vector expressing the human preproenkephalin A (PPE) gene with potential antinociceptive activity. Upon intradermal administration, PPE-expressing replication-defective HSV-1 vector NP2 is transported by retrograde axonal transport to the dorsal root ganglion (DRG) and becomes dormant. In the DRG, the vector transduces sensory neurons with high efficiency, delivering the engineered PPE gene; transduced neurons then express the protein proenkephalin A, the precursor for Met- and Leu-enkephalin. After proteolytic cleavage from proenkephalin A in the DRG neuronal cytosol, transgene-mediated Met- and Leu-enkephalin bind to mu and gamma- opioid receptors, which may result in the inhibition of nociceptive neurotransmission.
Industry:Pharmaceutical
A replication-defective adenoviral vector encoding human interferon-gamma (IFN-g) cDNA with potential antineoplastic and immunoregulatory activities. Upon intratumoral administration, the prolonged expression of IFN-g by adenovirus-interferon-gamma TG1042 promotes a T helper type 1 (Th1-type) immune response and inhibits the Th2-mediated cytokine production observed in many cutaneous lymphomas. IFN-g also mediates interleukin-12 (IL-12) production by antigen-presenting cells (APCs); activates macrophages, cytotoxic T-cells, and natural killer (NK) cells; upregulates major histocompatibility complex (MHC) molecules; and stimulates antibody-dependent cellular cytotoxicity (ADCC). Altogether, these IFN-g-mediated effects may result in an inhibition of tumor cell proliferation and tumor cell death.
Industry:Pharmaceutical
A replication-defective adenovirus containing a gene that encodes the human protein L523S with potential antineoplastic activity. Upon administration, recombinant adenovirus-L523S vaccine expresses L523S, which may stimulate antibody and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing L523S. L523S is an RNA-binding protein that belongs to the KOC (K homology domain containing protein over-expressed in cancer) family of proteins. As an oncofetal protein, L523S is normally expressed in early embryonic tissues and certain normal adult tissues such as colon, fallopian tube, gall bladder, and ovary tissues but may be overexpressed in squamous cell cancers of the lung.
Industry:Pharmaceutical
A replication-defective oncolytic adenovirus, encoding rat Her-2/neu (ErbB-2), with potential antineoplastic activity. Upon administration, adenovirus encoding rat HER-2/neu may induce an immune response against tumor cells expressing the HER-2/neu antigen, which may result in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. Her-2/neu, a tumor-associated antigen and member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumor cell types.
Industry:Pharmaceutical
A replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA) with potential antineoplastic activity. Adenoviral vector Ad5-CEA(6D) vaccine expresses a highly immunogenic analogue of CEA (CAP1-(6D)). Upon administration, this vaccine may induce both humoral and cellular immune responses against tumor cells expressing the CEA antigen, thereby resulting in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. CEA, a tumor-associated antigen, is overexpressed in various tumor cell types. Deletion of early genes E1 and E2b in Ad5 potentially circumvents pre-existing anti-adenovirus immunity and is capable of inducing strong immune responses.
Industry:Pharmaceutical
